91 related articles for article (PubMed ID: 19525194)
61. Gain of function of a metalloproteinase associated with multiple myeloma, bicuspid aortic valve, and Von Hippel-Lindau syndrome.
Snipas SJ; Jappelli R; Torkamani A; Paternostro G; Salvesen GS
Biochem J; 2022 Jul; 479(14):1533-1542. PubMed ID: 35789254
[TBL] [Abstract][Full Text] [Related]
62. Impact of High-Altitude Hypoxia on Bone Defect Repair: A Review of Molecular Mechanisms and Therapeutic Implications.
Chen P; Liu Y; Liu W; Wang Y; Liu Z; Rong M
Front Med (Lausanne); 2022; 9():842800. PubMed ID: 35620712
[TBL] [Abstract][Full Text] [Related]
63. Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers.
Zheng G; Sundquist K; Sundquist J; Chen T; Försti A; Hemminki O; Hemminki K
Eur Urol Open Sci; 2021 Feb; 24():52-59. PubMed ID: 34337496
[TBL] [Abstract][Full Text] [Related]
64. The DNA methylation landscape of hematological malignancies: an update.
Blecua P; Martinez-Verbo L; Esteller M
Mol Oncol; 2020 Aug; 14(8):1616-1639. PubMed ID: 32526054
[TBL] [Abstract][Full Text] [Related]
65. The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma.
Huang X; Gu H; Zhang E; Chen Q; Cao W; Yan H; Chen J; Yang L; Lv N; He J; Yi Q; Cai Z
Int J Cancer; 2020 Apr; 146(7):1963-1978. PubMed ID: 31390487
[TBL] [Abstract][Full Text] [Related]
66. Hypoxia-Modified Cancer Cell Metabolism.
Al Tameemi W; Dale TP; Al-Jumaily RMK; Forsyth NR
Front Cell Dev Biol; 2019; 7():4. PubMed ID: 30761299
[TBL] [Abstract][Full Text] [Related]
67. LINE-1 and EPAS1 DNA methylation associations with high-altitude exposure.
Childebayeva A; Jones TR; Goodrich JM; Leon-Velarde F; Rivera-Chira M; Kiyamu M; Brutsaert TD; Dolinoy DC; Bigham AW
Epigenetics; 2019 Jan; 14(1):1-15. PubMed ID: 30574831
[TBL] [Abstract][Full Text] [Related]
68. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
Dupéré-Richer D; Licht JD
Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
[TBL] [Abstract][Full Text] [Related]
69. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M
Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307
[TBL] [Abstract][Full Text] [Related]
70. Promoter Methylation Status Modulate the Expression of Tumor Suppressor (RbL2/p130) Gene in Breast Cancer.
Ullah F; Khan T; Ali N; Malik FA; Kayani MA; Shah ST; Saeed M
PLoS One; 2015; 10(8):e0134687. PubMed ID: 26271034
[TBL] [Abstract][Full Text] [Related]
71. T-cell lymphoma with von Hippel-Lindau disease: a rare case report and review of literature.
Lou LH; Shen H; Lin J; Yan YW; Peng Y; Lu JH; Xu Q; Jiang HQ
Int J Clin Exp Pathol; 2015; 8(5):5837-43. PubMed ID: 26191306
[TBL] [Abstract][Full Text] [Related]
72. Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma.
Stanojevic B; Saenko V; Todorovic L; Petrovic N; Nikolic D; Zivaljevic V; Paunovic I; Nakashima M; Yamashita S; Dzodic R
PLoS One; 2014; 9(12):e114511. PubMed ID: 25490036
[TBL] [Abstract][Full Text] [Related]
73. Cancer epigenetics: new therapies and new challenges.
Hatzimichael E; Crook T
J Drug Deliv; 2013; 2013():529312. PubMed ID: 23533770
[TBL] [Abstract][Full Text] [Related]
74. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.
Amodio N; Leotta M; Bellizzi D; Di Martino MT; D'Aquila P; Lionetti M; Fabiani F; Leone E; Gullà AM; Passarino G; Caraglia M; Negrini M; Neri A; Giordano A; Tagliaferri P; Tassone P
Oncotarget; 2012 Oct; 3(10):1246-58. PubMed ID: 23100393
[TBL] [Abstract][Full Text] [Related]
75. Biological aspects of angiogenesis in multiple myeloma.
Otjacques E; Binsfeld M; Noel A; Beguin Y; Cataldo D; Caers J
Int J Hematol; 2011 Dec; 94(6):505-18. PubMed ID: 22086206
[TBL] [Abstract][Full Text] [Related]
76. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
Kalac M; Scotto L; Marchi E; Amengual J; Seshan VE; Bhagat G; Ulahannan N; Leshchenko VV; Temkin AM; Parekh S; Tycko B; O'Connor OA
Blood; 2011 Nov; 118(20):5506-16. PubMed ID: 21772049
[TBL] [Abstract][Full Text] [Related]
77. Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease.
Hatzimichael E; Dranitsaris G; Dasoula A; Benetatos L; Stebbing J; Crook T; Bourantas KL
Clin Lymphoma Myeloma; 2009 Jun; 9(3):239-42. PubMed ID: 19525194
[TBL] [Abstract][Full Text] [Related]
78. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I
Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795
[TBL] [Abstract][Full Text] [Related]
79. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
Jensen RL; Gillespie D; House P; Layfield L; Shelton C
J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285
[TBL] [Abstract][Full Text] [Related]
80. The von Hippel Lindau tumour suppressor gene is a novel target of E2F4-mediated transcriptional repression in preeclampsia.
Alahari S; Garcia J; Post M; Caniggia I
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3298-3308. PubMed ID: 30053437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
